SecBot SecBot
SECBOTREPLAY Home › Report › ARVN

ARVN · Arvinas announced FDA approval of VEPPANU (vepdegestrant) for…

ARVINAS, INC. · 8-K filed May 1, 2026 at 12:58 ET

At the news

BULLISHIMPACT 8/10

8-K filed May 1, 2026 at 12:58 ET

Arvinas announced FDA approval of VEPPANU (vepdegestrant) for ER+/HER2-, ESR1-mutated advanced breast cancer, the first-ever approved PROTAC therapy. The approval came ahead of the June 5 PDUFA date, and Arvinas will receive a $50M milestone payment from partner Pfizer. This transformative milestone validates the PROTAC platform and provides a new treatment option in a high-need setting.

  • FDA approved VEPPANU (vepdegestrant) for ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer after prior endocrine therapy.
  • First-and-only FDA-approved PROTAC (protein degrader) therapy.
  • Approval received ahead of the June 5, 2026 PDUFA date.
  • In the Phase 3 VERITAC-2 trial, VEPPANU reduced risk of disease progression or death by 43% vs fulvestrant (HR 0.57, p=0.0001) in ESR1-mutated patients.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access